Vertex Pharmaceuticals Incorporated Earnings

Vertex Pharmaceuticals Incorporated’s revenue jumped 15.66% since last year same period to $2912Mn in the Q4 2024. On a quarterly growth basis, Vertex Pharmaceuticals Incorporated has generated 5.05% jump in its revenue since last 3-months.

Vertex Pharmaceuticals Incorporated’s net profit fell -5.76% since last year same period to $913Mn in the Q4 2024. On a quarterly growth basis, Vertex Pharmaceuticals Incorporated has generated -12.67% fall in its net profits since last 3-months.

Vertex Pharmaceuticals Incorporated’s net profit margin fell -18.52% since last year same period to 31.35% in the Q4 2024. On a quarterly growth basis, Vertex Pharmaceuticals Incorporated has generated -16.87% fall in its net profit margins since last 3-months.

Vertex Pharmaceuticals Incorporated’s earning per share (EPS) estimates for the current quarter stand at 4.02 - a -2.89% fall from last quarter’s estimates.

Vertex Pharmaceuticals Incorporated’s earning per share (EPS) estimates for the current year stand at 4.02.

Vertex Pharmaceuticals Incorporated’s earning per share (EPS) fell -5.24% since last year same period to 3.98 in the Q4 2024. This indicates that the Vertex Pharmaceuticals Incorporated has generated -5.24% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Vertex Pharmaceuticals Incorporated’s return on assets (ROA) stands at 0.13.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Vertex Pharmaceuticals Incorporated’s return on equity (ROE) stands at -0.03.